MedTech Innovator

Samay is a developer of an AI-enabled wearable device focused on remote respiratory health management, specifically targeting chronic obstructive pulmonary disease (COPD). The company's innovative chest patches utilize patented technology to diagnose COPD with 90% accuracy and identify exacerbation biomarkers at 83% accuracy, all while allowing patients to remain at home. The device continuously monitors various respiratory metrics, including pulmonary volumes, trapped air, respiratory and heart rates, breathing sounds, and temperature for up to two weeks. This real-time data collection empowers users to analyze their respiratory health and receive actionable insights to enhance their day-to-day well-being. Additionally, Samay is creating an AI-assisted management and diagnostic platform that supports both patients and doctors throughout the care continuum, from detecting exacerbations to determining effective therapies for more personalized treatment.

APrevent Medical Inc. is a medical device company based in Taipei, Taiwan, with an additional office in Austria. Founded in 2014, the company specializes in developing therapeutic devices aimed at enhancing the quality of life for patients affected by speech disorders. APrevent focuses on creating long-term implant systems and a speech conversion platform, along with other innovative medical equipment. Their offerings include minimally invasive ENT implants and Software-as-a-Service technologies designed to assist in the treatment of voice and communication disorders, enabling patients to improve their speech capabilities effectively.

FemTherapeutics Inc. is a Montreal-based medical device company with a mission to personalize therapeutics in women’s health. FemTherapeutics has developed an artificial intelligence platform that leverages patient data to design novel medical devices, and offer customization to achieve better clinical outcomes. Our first product involves the customization of gynecological prosthetics (or vaginal pessaries) to improve the management of Pelvic Floor Disorders in women.

EndoVision Limited, founded in 2018 and based in Hong Kong, specializes in the development of artificial intelligence software designed for computer-aided diagnosis in endoscopy. The company's innovative technology aims to enhance the accuracy and efficiency of medical diagnoses during endoscopic procedures, providing healthcare professionals with advanced tools to improve patient outcomes.

Niramai Health Analytix Private Limited is a Bengaluru-based company founded in 2016 that specializes in cancer screening solutions. Its primary product, Thermalytix, is a software that utilizes machine intelligence to analyze thermography images, enabling early detection of breast cancer. This innovative approach allows for the identification of tumors significantly smaller than those detectable by traditional methods, making it a critical tool for improving survival rates. Niramai’s offerings include a compact screening device for specialty hospitals, a handheld device for independent medical practitioners with real-time cloud-based diagnostics, and a portable solution suitable for large-scale screenings. The technology is designed to be cost-effective, non-invasive, painless, and free of radiation, allowing women across all age groups to undergo frequent screenings with minimal human supervision and side effects.

Progressive Neuro, Inc is a Silicon Prairie Center incubated medical device company dedicated to the development of Progressive Stroke Solutions. Progressive Neuro, Inc is focused on developing a unique portfolio of ischemic stroke devices that provide physicians with treatment options beyond aspiration and traditional thrombectomy.

Flow Medical specializes in the development of advanced multi-function catheters aimed at diagnosing and treating venous thromboembolic conditions, including pulmonary embolism. Their innovative platform enhances clot visualization and allows for the direct delivery of clot-dissolving medication to the blockage. Additionally, it enables real-time monitoring of treatment progress, empowering clinicians to tailor therapies to individual patient needs effectively. This approach positions Flow Medical as a key player in improving patient outcomes in the management of thromboembolic illnesses.

Fasciotens GmbH is a medical technology company based in Essen, Germany, founded in 2016. The company specializes in developing innovative devices for open abdomen therapy, which is crucial in treating severe infections, postoperative complications, and injuries that necessitate leaving the abdomen open. This therapy can be life-saving, particularly in cases such as abdominal compartment syndrome. Fasciotens' approach involves a unique method that maintains tension in the abdominal wall while increasing intra-abdominal volume. This technique combines the principles of mesh-mediated traction with those of an external fixator, ultimately enhancing the likelihood of successful outcomes for critically ill patients. Through its advanced solutions, Fasciotens aims to improve medical care in challenging surgical situations involving the open abdomen.

myBiometry is developing a platform to monitor/manage patients with chronic disease using biomarker data from proprietary sensors and ML to identify patients at risk of treatment failure. Our initial focus is asthma where treatment failure occurs over 46% of the time (11.5M US patients, $80 billion). We are developing a single use, disposable sensor and device to track a biomarker of inflammation in breath. The data determines changes in adherence, treatment response, and risk of attack.

Aurie is a medical device company based in New York, established in 2018. It focuses on developing a reusable urinary catheterization system aimed at improving the quality of life for individuals with disabilities. By providing a convenient, discreet, and hygienic catheterization option, Aurie seeks to reduce the risk of infections and enhance users' confidence and control over their healthcare needs. The company's innovative approach empowers users to manage their condition more effectively, enabling them to lead active and fulfilling lives.

CytoVeris is a company focused on developing optical-based technologies to assist surgical oncologists in identifying and removing tumor tissue during cancer resection surgeries. Founded in 2018 by Alan Kersey in Farmington, Connecticut, CytoVeris aims to enhance the surgeon's ability to achieve clean margins, thereby improving patient outcomes. The company’s devices facilitate real-time assessment of tissue and generate molecular-specific information by detecting unique signatures created by cancer cells that alter cellular metabolic processes. This includes variations in lipids, proteins, and metabolites, which can be identified using their OncoMap system. By providing oncologists with critical information during surgery, CytoVeris seeks to reduce healthcare costs associated with repeat surgeries.

Nanochon is focused on creating innovative implantable medical devices designed to address cartilage damage in joints. Utilizing advanced 3D printing techniques and a unique nanomaterial, the company aims to develop solutions that not only replace lost and damaged cartilage but also promote the growth of new tissue. This approach allows medical practitioners to access cost-effective and on-demand devices that enhance treatment outcomes, particularly for young and active patients suffering from knee injuries and diseases. Through its technology, Nanochon seeks to improve the overall quality of care in orthopedics.

DiaMonTech AG is a medical technology company based in Berlin, Germany, focused on developing non-invasive diagnostic devices for blood glucose monitoring. Founded in 2015, the company utilizes a proprietary laser-based photo-thermal detection technology to measure glucose levels without the need for blood draws or finger pricking, thereby offering a painless alternative for diabetes management. DiaMonTech's product lineup includes the D-BASE, a device designed for human trials, the D-pocket, a compact personal device for frequent glucose tracking, and the D-BAND, a wearable device that continuously monitors blood sugar levels. Through its innovative solutions, DiaMonTech aims to enhance the quality of life for individuals managing diabetes.

Dopl Technologies, co-founded by an ex-Microsoft engineer and two Harvard-trained experts, focuses on enhancing healthcare access for underserved populations, particularly in rural areas where healthcare resources are limited. The company has developed a telerobotic ultrasound system that allows specialists to conduct diagnostic ultrasound procedures remotely, addressing the issue of specialists being predominantly located in urban centers. This innovative platform aims to improve patient access to timely care, enhance health outcomes, and provide financial benefits to hospitals by reducing costs and increasing revenue. By leveraging technology, Dopl seeks to bridge the gap in healthcare availability and ensure that quality medical services reach those who need them most.

Craif Inc., previously known as Icaria Inc., is a Tokyo-based company founded in 2018 that specializes in developing innovative devices for early cancer detection through urine tests. The company's flagship product is a MicroRNA device that serves as a biomarker for identifying early-stage cancers. Craif aims to revolutionize cancer diagnosis by providing a method that is painless, accurate, and suitable for regular screening, addressing the critical need for early detection in order to significantly improve survival rates. Traditional cancer diagnostic methods often involve discomfort and lack the precision required for early-stage identification, which can lead to late-stage diagnoses when treatment options are limited. Craif's technology leverages exosome-based liquid biopsy tests that analyze ribonucleic acid, allowing for high sensitivity and specificity in distinguishing cancerous from non-cancerous samples.

TYBR Health is a medical device company based in Houston, Texas, founded in 2020 by Tim Keane and Alex Smith. The company focuses on developing a sprayable hydrogel designed to protect healing tissues and minimize internal scarring, a common complication following surgical procedures. This innovative hydrogel solution is delivered through a user-friendly device, making it suitable for both open and minimally invasive surgeries. By reducing scarring by 75% in preclinical studies, TYBR's product aims to enhance recovery and improve the healing response of tissues, ultimately benefiting patients who have undergone operations that risk damaging vital internal organs.

X-BOLT Orthopaedics developed a novel expanding bolt device, with associated implants and instrumentation systems, for internal bone fixation in osteoporotic hip fractures. X-BOLT hip plating and nailing systems allow surgeons choice to treat all morphologies of proximal femoral fractures.

SmartCardia’s platform combines medical wearable technology with Artificial Intelligence to provide unique insights into patient’s health. They have developed SmartNeuralNet, a world-leading machine learning technology that powers their medical wearables. Their mission is to empower the millions of patients with chronic conditions with actionable insights to improve their health.

Swift Duct develops a navigational tool for the ERCP procedure, which minimizes the risk of infections in the pancreas.

iCE Neurosystems develops a neuromonitoring platform that focuses on providing early warnings and guiding treatment for patients with brain injuries. By integrating innovative devices, advanced software, and big-data methodologies, the company offers healthcare professionals real-time insights into brain health. This approach allows doctors and nurses to diagnose and prevent brain injuries in critically ill patients, enhancing their ability to deliver timely and effective care.

INOPASE is a medical device company focused on the development of wirelessly powered, closed-loop implantable neuromodulation technologies. The company is currently advancing two key products: a closed-loop sacral neuromodulation system aimed at treating overactive bladder and a closed-loop brain neuromodulation device designed for epilepsy management. INOPASE's platform utilizes advanced algorithms to deliver personalized treatment plans by detecting symptoms and providing targeted stimulation therapy, positioning the company as a significant player in the treatment of chronic neurological diseases.

ATDev specializes in assistive technology and medical device solutions, focusing on the development of innovative mobility devices. These devices are designed to enhance physical therapy accessibility for patients in the United States and globally. By integrating robotics into their solutions, ATDev aims to transform traditional physical therapy practices, facilitating improved patient outcomes and enabling healthcare providers to overcome challenges related to care delivery. Their technology specifically addresses the needs of individuals recovering from knee surgery, thereby enhancing the quality of care and support during rehabilitation.

Butterfly Medical Ltd is a medical device company based in Yokne'am, Israel, founded in 2014. The company specializes in developing an innovative implantable device designed to treat Benign Prostatic Hyperplasia (BPH), commonly known as enlarged prostate. This device offers a fast, simple, and minimally invasive alternative to conventional BPH treatments, such as medication and surgery. It can be placed in under ten minutes in an office setting, using local anesthesia and without the need for surgical incisions or tissue removal. This approach aims to provide a long-term solution with minimal side effects, eliminating the need for hospitalization or general anesthesia. Early clinical trials have shown promising results, with effective outcomes in relieving blocked urethras and no reported side effects. Butterfly Medical is advancing further clinical studies at leading medical centers in Europe to validate its device's efficacy and safety.

Salvia BioElectronics B.V., founded in 2017 and headquartered in Eindhoven, the Netherlands, focuses on developing bioelectronic therapies for individuals with chronic neurological conditions, particularly chronic migraines. Drawing its name from the Latin word for "to stay healthy," Salvia is committed to providing drug-free, effective, and side-effect-free solutions. The company leverages a team of experienced professionals, including entrepreneurs, engineers, and scientists, who have extensive backgrounds in the medical device industry. Salvia aims to make its innovative bioelectronic solutions widely accessible, addressing the needs of patients seeking alternative treatments for their conditions.

Ortho-tag specializes in developing innovative technologies that facilitate wireless communication between digital health applications and implanted medical devices. Their in-vivo platform enables real-time data exchange and in-body communication through a proprietary method known as transcutaneous volume conduction. This technology enhances the functionality of smart medical implants by allowing for efficient powering, data storage, and nano diagnostic capabilities. By bridging the gap between digital health technologies and the human body, Ortho-tag aims to improve the integration and performance of medical devices, thereby enhancing patient care and monitoring.

Promedius, established in 2019, focuses on transforming the approach to aging by developing innovative solutions for the early detection and management of musculoskeletal and metabolic diseases, particularly osteoporosis. The company aims to improve the quality of life and extend healthy lifespans through advanced technology. Its flagship product, PROS® CXR:OSTEO, is a pioneering screening solution that utilizes chest X-ray images to identify individuals at risk of osteoporosis. By employing artificial intelligence in medical imaging, Promedius provides medical professionals with efficient tools to prevent severe fractures among the elderly population, thereby contributing to better health outcomes and enhancing patient care.

Nanobiofab, founded in 2015 and based in Frederick, Maryland, specializes in the development of wearable, smart healthcare and medical devices utilizing nanotechnology for both humans and pets. The company is known for its product, iNose, which enables users to detect, track, and monitor their body's skin vapor-print. This device wirelessly connects to mobile phones to help individuals assess their fat burning rate and evaluate the effectiveness of their exercise routines. Additionally, it provides insights into the effects of dietary choices over time and tracks metabolic rates. Beyond consumer products, Nanobiofab also offers technology and services aimed at accelerating nanomaterial research and development, including nanoprinting solutions and artificial intelligence sensors for telemedicine and personalized healthcare applications.

Nanotis is a company which Solve various problems in infectious disease tests such as influenza.

Juniper Biomedical is a medical device company focused on implantable neuromodulation technology aimed at improving pelvic health. The company has developed a micro-implant that provides precision treatment for various pelvic health conditions by modulating distal target nerves locally. This technology specifically stimulates only the target nerves, allowing for less invasive and safer therapeutic options. It addresses a range of issues, including incontinence, sexual dysfunction, and chronic pain, offering patients more effective solutions for managing their health concerns.

Neurovalens Limited specializes in the development of non-invasive neurostimulation medical devices aimed at addressing global health challenges such as obesity. Founded in 2013 and headquartered in Ballymena, United Kingdom, the company offers products like Stimu Slim and Modius, which are electronic headsets designed to influence brain activity and support weight management. Neurovalens employs advanced technologies to activate specific brain regions, enabling adjustments in autonomic function and neuro-metabolic processes. The company has received funding from Invest NI as part of the European Union’s Investment for Growth and Jobs Programme to support its research and development initiatives, enhancing its competitiveness in the field of neuroscience and bioscience.

StrokeDx develops rapid and portable devices to transform how strokes are diagnosed. The company's full-time software engineering team works on novel algorithms using machine learning and AI approaches to fuel the diagnostic accuracy and imaging capabilities of the StrokeDx sensor.

Fingy3D is a company focused on making prosthetic devices accessible to individuals, specifically targeting finger prosthetics. Utilizing an AI scanner, the company accurately measures the user's finger dimensions and generates a custom prosthetic that is 3D printed. This innovative approach allows customers to receive personalized finger prosthetics conveniently at their doorsteps, ensuring that even the smallest digit can be replaced and made functional. Fingy3D aims to enhance the quality of life for those in need of prosthetic solutions.

Plio Surgical is a company in the medical devices sector focused on developing innovative solutions for intestinal anastomosis procedures. The firm has created a device that is laparoscopically deployed into the healthy lumen of the bowel. Once the bowel heals, the device detaches and passes naturally, leaving no foreign material in the body. This technology aims to simplify the surgical process and enhance patient outcomes by addressing unmet clinical needs in gastrointestinal surgery.

Sonavi Labs, Inc. is a Baltimore-based company that specializes in the development of medical devices and artificial intelligence-based software aimed at respiratory monitoring and diagnostic support. Founded in 2017, the company focuses on creating innovative products that analyze body sounds to assist in the diagnosis of respiratory diseases. By leveraging advanced technology, Sonavi Labs enables healthcare providers to detect, monitor, and potentially predict respiratory conditions by identifying abnormalities in the sounds produced by the body. This approach enhances the capabilities of medical professionals and aims to improve the patient experience in managing respiratory health.

Pumpinheart is a heart failure treatment system with preserved ejection fraction (HFpEF).

INVENIO IMAGING, Inc. is a privately held corporation founded in 2012 based on the research of Prof. Sunney Xie of the Department of Chemistry and Chemical Biology at Harvard University. Invenio is dedicated to developing a fast, reliable, simple-to-use technology for non-destructive microscopic analysis of the molecular make-up of tissues and other materials. INVENIO’s platform technology is positioned to enter the R&D microscopy market, and it is developing instrumentation for several high-value medical applications. INVENIO IMAGING Inc. acknowledges funding from the NSF and NIH SBIR programs.

Averto Medical is a manufacturer of medical devices focused on addressing gastrointestinal diseases. The company specializes in developing innovative solutions designed to facilitate minimally invasive colorectal tumor removal, which aims to reduce the need for multiple surgical procedures and associated complications. By providing effective medical care options for patients suffering from gastrointestinal disorders, Averto Medical seeks to improve patient outcomes and streamline treatment processes in this critical area of healthcare.

Fingy3D is a company focused on making prosthetic devices accessible to individuals, specifically targeting finger prosthetics. Utilizing an AI scanner, the company accurately measures the user's finger dimensions and generates a custom prosthetic that is 3D printed. This innovative approach allows customers to receive personalized finger prosthetics conveniently at their doorsteps, ensuring that even the smallest digit can be replaced and made functional. Fingy3D aims to enhance the quality of life for those in need of prosthetic solutions.

Purgo Scientific is a medical device company focused on developing an innovative drug delivery system aimed at addressing the challenges posed by biofilm infections in orthopedic surgery. The company's technology is designed to create a sustainable, localized delivery method that targets therapeutic drugs directly to the site of infection, thereby treating and preventing biofilm-related surgical site infections that can affect orthopedic implants. This approach not only aims to eradicate infections caused by biofilms but also has potential applications in managing various health issues that benefit from precise medicine delivery, including pain management and oncology.

Medical Devices Corner is a company focused on developing innovative medical devices aimed at enhancing cancer diagnosis and treatment. Their primary offering is a novel robotic system designed to facilitate minimally invasive surgeries. By advancing device technology, the company supports healthcare professionals in performing procedures that include biopsies and ablations with reduced invasiveness. Through its commitment to improving surgical techniques, Medical Devices Corner plays a crucial role in the health industry, striving to enhance patient outcomes and streamline medical processes.

CORIT Medical LLC is a commercial medical device company located in McLean, VA, with a specific focus on a Class I single-use surgical device to improve breathing. The established Ear, Nose & Throat (ENT) procedure is called inferior turbinate reduction and has an existing reimbursement code. There are currently 1 million procedures performed in the US each year, and reportedly over 50 million people who suffer from obstructed breathing. The patented CORIT device is hand-powered requiring no expensive equipment to set up and operate. It has also shown to produce more durable results in contrast with competing technologies that can return to pre-treatment baseline levels of obstruction in as few as six months. ENTs are lined up, ready to buy the device, as they can complete the procedure in in a fraction of the time, right in their office (as opposed to an operating room), yielding a higher reimbursement.

Thermidas is a Finnish health technology company dedicated to developing and advancing infrared thermal imaging for diagnostic use.

Vitestro is a company focused on enhancing patient care through innovative autonomous blood drawing technology. It develops medical robotic devices tailored for use in hospitals and clinical laboratories. The company’s key product utilizes multi-dimensional ultrasound to detect nerves and arteries, leveraging deep learning to minimize the risk of arterial complications during blood draws. This advanced technology not only aids healthcare professionals in performing procedures with greater precision but also aims to improve overall patient health outcomes by reducing complications associated with traditional blood collection methods.

Neurava is a company focused on developing non-invasive wearable diagnostic devices for patients with epilepsy, particularly those at risk of Sudden Unexpected Death in Epilepsy (SUDEP). The company's innovative device monitors critical biological signals related to epilepsy, providing timely alerts to caregivers and patients. By offering a reliable monitoring solution, Neurava aims to enhance patient autonomy and deliver peace of mind to families, facilitating timely intervention when necessary. The company's work lies at the intersection of medical device manufacturing and health diagnostics, addressing a significant need within the epilepsy patient community.

Adcura, Inc. is a medical device company specializing in minimally invasive implant products aimed at enhancing the quality of life for patients with spine-related conditions. The company develops a range of innovative products, including retractors, disposable accessories, and adjustable lumbar fusion devices, which are designed to address existing surgical inefficiencies. By focusing on precision technologies and surgical techniques, Adcura enables medical practitioners to improve surgical outcomes while reducing post-operative complications for patients.

Xtremedy Medical is a medical technology based at NUI Galway that manufactures surgical devices to treat bone and deep tissue infections by sending electrical signals through wounds, both on the surface and below, to eliminate any residual infection.

Happitech is a pioneering company that offers a CE Certified heart rate software development kit (SDK) for Android and iOS, facilitating remote patient management through mobile applications. By integrating Happitech's algorithms, users can monitor vital signs, including heart rate and heart rate variability, utilizing only a smartphone camera. The technology is backed by clinical evidence and powered by AI, making it suitable for various applications such as cardiovascular screening, stroke prevention, and telehealth services. Happitech's solutions are designed to enhance care management, support health practitioners, and empower patients globally. The company has received multiple accolades, including recognition as one of the top Dutch COVID-19 healthcare companies and awards for its innovative contributions to digital health.

Houston-based medical device startup Prana Thoracic, Inc. is dedicated to developing solutions for early intervention in lung cancer. We are an experienced team of surgeons, engineers and entrepreneurs on a mission to tackle lung cancer; the #1 cancer killer in the US. The paradigm of screening, detection, and early intervention that has been deployed in other major cancers has so far eluded lung cancer. As a result, only 16% of lung cancers are found at an early stage and the current 5-year survival rate is < 20%. Recent changes to lung cancer screening guidelines have illuminated a path to improving outcomes in lung cancer. However, these advances rely on excising suspicious nodules and providing sufficient tissue for definitive diagnosis. We believe this is the missing piece of the puzzle, and physicians need a new generation of surgical oncology tools for lung cancer. Prana Thoracic plans to revolutionize the early diagnosis and treatment of lung cancer by making it easier and less invasive to deal with the rapidly growing number of early suspicious lung nodules; ensuring that we do not miss the window of opportunity to intervene early.

Mirai Medical is a medical device company focused on developing innovative technologies for cancer therapy. Its unique intellectual property allows for the painless delivery of electroporation energy through endoscopic procedures, significantly improving the treatment of cancer. This technology enables endoscopists to perform pulse field ablation safely and efficiently, ultimately aiming to enhance patient outcomes and experiences in cancer treatment.

Sparta Biomedical develops cartilage-like implants for the knee. They specialise in the creation of biomimetic implants that require minimally invasive therapy for chondral or osteochondral knee cartilage abnormalities, providing orthopaedic surgeons with enhancements that fundamentally restore movement for their patients.

NeuraStasis is focused on developing a non-invasive electrical neurostimulation method aimed at preventing strokes. The company has created a novel device that activates the body's natural oxygen-preserving and anti-inflammatory reflexes, which helps to preserve brain tissue during critical moments. This approach not only delays brain damage but also provides healthcare providers with additional time to intervene effectively. Ultimately, NeuraStasis seeks to empower patients to leave the hospital without disabilities following a stroke, enhancing recovery outcomes and improving quality of life.

CerebraAI is a digital diagnostic company focused on improving stroke diagnosis through advanced artificial intelligence technology. Since its inception in 2018, the company has developed CEREBRA, an AI-powered software that enhances the efficiency of CT machines. This software enables rapid detection of acute ischemic stroke within five minutes using non-contrast computed tomography, facilitating quicker and more accurate treatment for patients. By empowering community hospitals with these innovative tools, CerebraAI aims to optimize patient outcomes in neuroradiology and address the critical time sensitivity associated with stroke care.

StrokeDx develops rapid and portable devices to transform how strokes are diagnosed. The company's full-time software engineering team works on novel algorithms using machine learning and AI approaches to fuel the diagnostic accuracy and imaging capabilities of the StrokeDx sensor.

Healthcare is moving to the outpatient setting to save costs, but at home patients struggle with medication adherence and they are readmitted at alarming rates. Hospitals send 1.4 million patients home for 4-6 weeks to administer their own IV antibiotics every year. Twenty percent of patients on outpatient parenteral antimicrobial therapy (OPAT) are readmitted, each costing $80,000 on average. This is a $22.4 billion problem. Clinicians at the 12,200 home infusion providers in the US have no objective way to identify non-adherence to intervene and prevent readmissions. Rather, they call patients to detect non-adherence, which is time-consuming, inaccurate, and prone to reporting bias. They need a better tool than a phone to monitor adherence. The solution is HIVE’s patent pending CloudConnect smart catheter. CloudConnect is a reinvented IV line with a simple embedded mechanoelectrical sensor that detects when a medication source is connected. CloudConnect wirelessly sends this information to electronic medical records. HIVE’s value proposition is that clinicians can detect non-adherence in real time and make treatment decisions and prevent costly readmissions based on objective data. HIVE offers CloudConnect as an alternative to the need for clinicians to call every patient with standard IV lines.

Total Flow Medical is a medical device startup focused on enhancing the quality of life for patients undergoing cardiac surgery and life support. The company is developing innovative medical devices aimed at preventing injuries in patients who require extracorporeal circulation. Its initial product is a user-friendly cannula designed for minimally invasive cardiopulmonary bypass surgery, which helps reduce the risks of injury and death associated with traditional invasive procedures.

Endocision is focused on creating innovative minimally-invasive medical devices aimed at enhancing the diagnosis and treatment of lung diseases. The company specializes in technologies compatible with bronchoscopy and robotic bronchoscopy, offering solutions that include a cryo-biopsy platform. These advancements enable healthcare professionals to effectively diagnose and manage conditions such as interstitial lung disease and lung cancer. By prioritizing safety and efficacy, Endocision seeks to improve patient outcomes in the field of pulmonary medicine.

AMI Corp specializes in medical consulting and the development of medical devices, focusing on telehealth solutions. The company offers a range of telemedicine services, which include a unique stethoscope system designed for remote auscultation. This innovative technology allows for the transmission of heart sounds as both audible and visual data, facilitating better access to medical care for patients through telehealth initiatives. AMI Corp aims to enhance the delivery of healthcare services by leveraging advanced communication methods in the medical field.

Senseye, Inc. is a company based in Los Angeles, California, focused on developing smart contact lenses that non-invasively gather data from users. Founded in 2015, the company aims to infer human emotions, thoughts, and health states to support various applications in market research, disease diagnosis, and early detection of conditions such as strokes and heart attacks. By utilizing innovative measurements of ocular physiology, Senseye quantifies cognitive abilities, health metrics, and psychological well-being, including vital signs and cognitive load. The platform is designed to enhance clinicians' ability to provide personalized care, allowing them to establish baselines and monitor patient outcomes effectively. As the technology advances, Senseye intends to place greater emphasis on emotional responses and mental health diagnostics, offering new insights into cognitive and health parameters through standard camera equipment.

VeinWay is a medical device company focused on developing innovative solutions for chronic venous occlusions caused by blockages or disease. The firm has created a specialized catheter designed to assist physicians in recanalizing obstructed veins, facilitating the restoration of blood flow to the heart. This platform provides a dedicated tool that enables medical professionals to navigate complex blockages that were previously deemed uncrossable, thereby improving the efficiency and safety of venous treatments. By addressing the challenges associated with chronic venous disease, VeinWay aims to transform the approach to treating these conditions.

Perceptive Medical is a developer of medical devices focused on enhancing blood pressure management in critical care settings, specifically in intensive care units (ICUs) and operating rooms. The company's products are designed to integrate seamlessly into modern clinical workflows, providing precision in therapy and addressing inefficiencies in blood pressure management. By enabling measurable improvements in patient care, Perceptive Medical aims to support clinical providers in delivering better outcomes for patients undergoing critical treatment.

Xcision Medical Systems, LLC is a medical technology company focused on developing advanced stereotactic radiotherapy solutions, particularly for breast cancer treatment. The company's innovative device utilizes stereotactic gamma irradiation, allowing patients to complete their radiation therapy in a single, noninvasive session, rather than over several weeks. This approach not only significantly reduces the duration of treatment but also minimizes radiation exposure to surrounding healthy tissues, including the lungs and heart. By enhancing the quality of cancer care, Xcision aims to improve patient outcomes and enable individuals to return to their daily lives more quickly and with less discomfort.

Digma Medical is a clinical stage medical device company revolutionizing the treatment of Type-2 Diabetes and other metabolic syndrome disease such as NASH. Founded in 2013 and backed by leading venture capital firms, Digma is dedicated to the development of the DiaGone™ to treat insulin resistance - the underlying mechanism of the disease. The DiaGone™ is an endoscopic, disposable device, that uses state of the art laser technology to treat the duodenum without an implant. The Duodenal Glycemic Control™ procedure is a one-time 30 minute GI procedure, in which the gastroenterologist uses the DiaGone™ to treat the duodenum for restoring the natural ability of the body to control glucose levels, which may provide long term remission from Type-2 Diabetes, NASH, and other metabolic syndrome related disease.

Corveus Medical is developing a new way to prevent heart failure. It is a neuromodulation device that can uniquely reach tissues, unlocking a new field of heart failure treatment. Its goal is to develop a device that safely accesses tissue, providing consistent results.

CardiaCare is a developer of a wearable medical device aimed at the non-invasive treatment and monitoring of atrial fibrillation (AFib) in patients at home. The device employs a closed-loop approach and machine learning algorithms to deliver personalized peripheral neuromodulation therapy. This innovative technology mediates a cardiovascular antiarrhythmic response, helping users to alleviate the burden of atrial fibrillation and address precursors such as premature atrial contractions. As a result, CardiaCare’s device offers users the potential for rapid clinical and symptomatic relief.

LiveMetric is a medical device company focused on developing non-invasive sensing and deep data analytics solutions aimed at transforming the management of hypertension and cardiovascular diseases. The company has created a wearable, cuff-free device for blood pressure monitoring, which has received FDA clearance and is validated for accuracy against traditional arterial line measurements. This device offers continuous monitoring of vital signs, enabling healthcare providers to deliver AI-augmented care and treatment management. LiveMetric aims to empower patients, payors, and healthcare professionals with accurate, personalized data, facilitating better decision-making and improving the overall quality of care for individuals suffering from chronic cardiovascular conditions. By providing detailed daily activity mapping and real-time feedback, the company seeks to enhance the lives of millions worldwide affected by these health issues.

MicroGEM is a microbiology research company focused on democratizing molecular biology by transferring complex molecular biology techniques from specialized laboratories to non-laboratory environments. The company employs an innovative enzymatic method for nucleic acid extraction, which facilitates sample preparation compatible with PCR (polymerase chain reaction) analysis. This technology supports the development of portable diagnostic devices aimed at managing infectious diseases and enhancing personalized medicine applications, making advanced molecular biology accessible to a broader audience.

Leadoptik is a deep-tech company focused on developing advanced miniature imaging technology designed for minimally invasive medical procedures. Its platform enhances surgical capabilities by providing high-resolution imaging and 3D navigation in real time, allowing surgeons to visualize small anatomical structures with greater clarity than existing imaging systems. This innovative approach facilitates the early detection of cancer and improves the overall effectiveness of surgical interventions, ultimately contributing to better patient outcomes.

CloudMedx Inc. is a software development company that specializes in artificial intelligence solutions aimed at extracting critical clinical insights from electronic health records. Founded in 2014 and based in Palo Alto, California, the company transforms raw healthcare data into actionable insights that enhance clinical operations, documentation, and patient care. Its platform leverages population health history to improve clinical, treatment, and diagnostic outcomes, while also notifying physicians when care is necessary. CloudMedx provides patient-centric tools that facilitate engagement, risk stratification, and actionable insights, serving a range of healthcare entities including managed care organizations, accountable care organizations, physician-led organizations, emergency rooms, urgent care facilities, and lab testing sites. The company’s mission is to unify healthcare systems, enabling better collaboration among providers, payers, and patients, ultimately improving the accuracy and quality of care delivered.

EvoEndo specializes in developing innovative systems that facilitate unsedated endoscopic procedures for both pediatric and adult patients. The company combines sterile, single-use, multi-specialty flexible endoscopes with a virtual reality-based distraction method, allowing patients to undergo routine endoscopies without the need for general anesthesia or sedation. This approach not only reduces the complexity and cost of the procedures but also alleviates patient and provider apprehension. EvoEndo's comprehensive software integration platform further enhances the effectiveness of its technology, streamlining the endoscopic process and promoting a more comfortable experience for patients.

Aqua Medical, Inc. is focused on developing innovative, vapor-based, endoscopic ablation technology aimed at treating gastrointestinal diseases and preventing gastrointestinal cancers. Founded in 2016 and based in Santa Ana, California, the company utilizes high-temperature water vapor generated by a radiofrequency generator. This vapor is delivered endoscopically through proprietary catheters, allowing for a minimally invasive approach to treat various conditions within the gastrointestinal tract, including pancreatic cysts and esophageal issues. Aqua Medical's platform technology offers a convenient and effective alternative to traditional surgical methods, enhancing treatment options for medical practitioners and their patients.

Tricog Health specializes in developing advanced cardiac diagnostic tools aimed at addressing cardiovascular conditions with precision and timeliness. Utilizing medical-grade artificial intelligence, Tricog's solutions facilitate real-time reporting and analysis of electrocardiography results, enabling healthcare providers to identify cardiac issues quickly and accurately. The company focuses on bridging gaps in cardiac care infrastructure, expertise, and efficiency, ensuring that patients receive prompt diagnoses and timely interventions. Tricog is dedicated to enhancing cardiac care accessibility by providing virtual diagnostic tools and services, thereby supporting healthcare professionals in delivering reliable and consistent patient care.

MindMics is an innovative wearable technology company focused on health monitoring through sound-based platforms integrated into earbuds and hearing aids. By capturing clinically meaningful biometrics in real-time, such as circadian rhythms, breathing rates, body temperature, and heartbeats, MindMics aims to enhance mental performance and overall well-being. The technology allows users to gain insights into their health, facilitating improved focus, satisfaction, and mindfulness. Through this approach, MindMics seeks to provide users with tailored products and experiences that promote mental peace and enhance daily living.

MeaCor Inc., based in Montreal, Canada, specializes in the development of innovative transcatheter devices designed to address heart disease, particularly valvular conditions. The company manufactures a catheter-based medical device aimed at repairing the mitral and tricuspid valves, utilizing an anchoring catheter system to facilitate these procedures. This technology focuses on transcatheter interventions that minimize the risks and trauma typically associated with conventional surgical methods. By doing so, MeaCor enables effective treatment for patients who are not candidates for traditional surgery, specifically targeting those suffering from mitral valve regurgitation.

Woven Orthopedic Technologies, LLC is a medical device company based in Manchester, Connecticut, specializing in the design and development of orthopedic technologies. Founded in 2013, the company focuses on enhancing the screw-to-bone interface to address the loss of screw fixation, a common challenge in orthopedic procedures. Its innovative devices are manufactured from biopolymers, which increase surface area contact between the bone and screws, distribute load transfer to facilitate bone healing and remodeling, and promote bone ingrowth for improved fixation. By leveraging biotextile technology, Woven Orthopedic Technologies aims to provide effective solutions for orthopedic surgeons, ultimately making advanced treatments more accessible and efficient for patients. The company is dedicated to tailoring orthopedic solutions to meet individual patient needs while ensuring that these technologies remain widely available.

DermaSensor, Inc. is a Miami-based company that develops a handheld device designed to evaluate skin lesions for cancer using artificial intelligence and spectroscopy. Founded in 2009, the company's flagship product enables both physicians and consumers to conduct skin checks conveniently in clinical settings and at home. The device employs elastic scattering spectroscopy and machine learning algorithms to rapidly assess skin lesions, helping to identify potential cancerous cells. By providing an affordable and efficient tool for early detection, DermaSensor aims to improve access to skin cancer evaluations, addressing the significant number of Americans who have never undergone such checks. The technology not only facilitates immediate assessments but also alerts users when cancerous cells are detected, streamlining the process of skin cancer diagnostics.

Moon Surgical is a medical device company focused on enhancing laparoscopic surgery through its innovative Maestro System. This system is designed to facilitate access to minimally invasive surgical techniques while optimizing resource utilization in the operating room. By providing features such as stabilization and automatic positioning of endoscopes, along with organ retraction, the Maestro System aims to improve surgical efficiency and patient care. Moon Surgical's technology allows surgeons to maintain their existing workflows and techniques, integrating the advantages of robotic assistance without disrupting traditional practices. Through its commitment to advancing surgical technology, Moon Surgical seeks to transform the landscape of surgery today.

SymPhysis Medical's goal is to develop innovative technologies that treat a range of chronic diseases, putting the patient experience at the forefront of our design solutions to improve quality of life. About SymPhysis MedicalSymPhysis Medical's emergent technology, releaze, is a drainage technology to treat a common complication of late-stage cancers, malignant pleural effusion (MPE). MPE causes significant shortness of breath and chest pain in up to 15% of patients with cancer.

Limax Biosciences focuses on transforming tissue healing both internally and externally through its innovative products. The company has developed a degradable adhesive hydrogel that is designed for hemostasis, wound closure, and drug delivery. This hydrogel is characterized by its strong, stretchy, and flexible properties, which are derived from bio-inspired materials. By providing a reliable solution for sealing wounds and promoting healing, Limax Biosciences enables healthcare professionals to utilize its technology across various medical applications.

Liquet Medical is a medical device development company that transforms the way the vascular disease is treated through localized drug delivery. The Versus Catheter will be Liquet Medical’s first technology to market.

Gravitas Medical, founded in 2015 and based in San Francisco, California, focuses on developing a personalized automated nutrition management system tailored for hospital settings. The company's innovative nasogastric feeding system evaluates patient readiness for feeding and enhances the delivery of nutrition. By optimizing these processes, Gravitas Medical aims to improve patient health outcomes, decrease overall healthcare costs, and alleviate the workload of nursing staff.

Discure Technologies is developing a minimally invasive, implantable bioelectronic device designed to treat and reverse degenerative disc disease (DDD), healing the disc, reducing pain, and restoring function to patients.

Endiatx, Inc. is a medical device manufacturing company based in Redwood City, California, specializing in innovative pill-sized robots designed for remote diagnostics and treatment within the gastrointestinal (GI) tract. Founded in 2019, the company has developed the Endiatx Pill Surgeon and the Endiatx Pill Robot, both of which feature advanced propulsion systems that allow them to navigate the entire length of the GI tract in about 30 minutes. These devices provide real-time video control, enabling physicians to perform sedation-free endoscopies in challenging areas, thus enhancing diagnostic capabilities and patient comfort.

ConKay Medical Systems is an early-stage medical device company advancing solutions to treat valvular regurgitation in patients with progressive heart failure.

Neurovalens Limited specializes in the development of non-invasive neurostimulation medical devices aimed at addressing global health challenges such as obesity. Founded in 2013 and headquartered in Ballymena, United Kingdom, the company offers products like Stimu Slim and Modius, which are electronic headsets designed to influence brain activity and support weight management. Neurovalens employs advanced technologies to activate specific brain regions, enabling adjustments in autonomic function and neuro-metabolic processes. The company has received funding from Invest NI as part of the European Union’s Investment for Growth and Jobs Programme to support its research and development initiatives, enhancing its competitiveness in the field of neuroscience and bioscience.

Endoron Medical specializes in the development of medical devices aimed at improving the treatment of abdominal aortic aneurysms. The company focuses on creating an endovascular suture device that enhances the effectiveness of endovascular aneurysm repair procedures. By designing long-lasting sealing equipment for endografts, Endoron Medical provides healthcare professionals with advanced technology to treat patients more effectively. This innovation is intended to improve patient outcomes and streamline surgical processes in the management of abdominal aortic aneurysms.

PyrAmes has developed a paper thin, flexible, ultra low power device for non-invasive monitoring of blood pressure

Forest Devices, Inc. is a medical device company based in Pittsburgh, Pennsylvania, with an additional office in Canada. Founded in 2014, the company focuses on developing innovative solutions for stroke detection. Its primary product, AlphaStroke, is a portable and non-invasive stroke screening device that assists medical personnel in identifying early signs of both ischemic and hemorrhagic strokes. This device is designed to be low-cost and durable, enabling pre-hospital providers to triage patients effectively and make timely decisions regarding their care. By improving the speed and accuracy of stroke detection, Forest Devices aims to reduce delays in critical treatment for patients experiencing strokes.

OncoRes Medical is an early-stage medical device company based in Perth, Western Australia, focused on developing an innovative imaging technology that enhances intraoperative surgical procedures. This technology, which employs a novel combination of optical coherence tomography, aims to improve surgical accuracy and reduce complication rates during breast cancer surgeries by providing real-time information that helps surgeons distinguish between tumor and healthy tissue. In collaboration with leading researchers from the University of Western Australia and the Harry Perkins Institute of Medical Research, as well as breast cancer surgeons within the Western Australian public health system, OncoRes Medical is advancing its patent-protected technology. The company is supported by funding from the Medical Research Commercialisation Fund, with the goal of transforming the standard of care in clinical applications that require detailed assessment of tissue microstructure.

HD Medical specializes in innovative cardiovascular diagnostic solutions, focusing on the development of a visual stethoscope that integrates electrocardiogram (ECG) technology. This device enables healthcare professionals to visualize heart sounds and cardiac waveforms in real time at the point of care. By allowing for the recording of results, the stethoscope facilitates the early detection and management of cardiovascular diseases. In addition to its diagnostic tools, HD Medical also offers patient diagnosis and treatment services, contributing to improved outcomes in cardiac health.

Sepsis Scout is a developer of a wearable patch aimed at predicting the onset of sepsis in high-risk patients in a home care setting. The device utilizes proprietary deep learning technology to enhance the accuracy of sepsis predictions compared to current standards of care. By enabling patients to monitor their health more effectively, Sepsis Scout's solution helps manage chronic illnesses and reduces the need for hospital visits, alleviating the fear and uncertainty associated with serious health conditions.

ATRO Medical B.V., based in Nijmegen, the Netherlands, focuses on developing innovative solutions for knee joint health through its anatomically shaped meniscus implant, the Trammpolin. This implant is designed to restore the protective function of the meniscus by acting as a joint spacer, thus alleviating pain and improving life quality for patients suffering from osteoarthritis. The company emerged as a spin-out from DSM and Radboudumc, leveraging insights gained from a collaborative initiative that began in 2010, involving various universities and private enterprises with support from the Dutch government. The Trammpolin prosthesis is a synthetic, non-resorbable substitute that mimics the natural meniscus, functioning effectively as a shock absorber by ensuring adequate load distribution within the knee joint.

CoapTech, Inc. is a medical device company based in Baltimore, Maryland, specializing in ultrasound-based solutions for the placement of feeding tubes. Founded in 2016, CoapTech has developed the Point-of-care Ultrasound Magnet Aligned (PUMA-G) System, which mitigates risks associated with traditional methods such as PEG blind sticks, endoscope reprocessing, and fluoroscopy by allowing for ultrasound visualization from the stomach wall to the surface. The company also offers a procedure known as Percutaneous Ultrasound Gastrostomy (PUG), designed for critical care physicians and non-surgical providers to simplify the insertion of gastrostomy tubes. Utilizing a proprietary technology called Coaptive Ultrasound, CoapTech combines magnetic device guidance with real-time ultrasound feedback, aiming to improve safety, reduce healthcare costs, and enhance patient care experiences. Their focus on the PUG procedure highlights a commitment to innovation, safety, and accessibility in medical care delivery across various patient populations.

Previvo is a medical device compamy dedicated to preventing genetic disease using our patent-pending technology to facilitate pre-implantation genetic testing.

Subtle Medical, Inc. is a healthcare technology company based in Menlo Park, California, that specializes in developing AI-powered medical imaging software for clinical imaging centers and hospitals. Founded in 2017, the company offers products such as SubtleMR and SubtlePET, both of which are FDA cleared and CE marked. These technologies enhance image quality in magnetic resonance imaging (MRI) and positron emission tomography (PET) exams by reducing noise and increasing sharpness, ultimately improving workflow efficiency while ensuring patient safety. Subtle Medical also features SubtleGAD, a technology recognized by the Radiological Society of North America, which aims to make imaging exams safer. The company employs a vendor-agnostic AI infrastructure that integrates seamlessly with existing scanners, allowing imaging providers to serve more patients effectively by enhancing image acquisition without disrupting their current workflow. Through its innovations, Subtle Medical seeks to improve the quality, value, and accessibility of medical imaging while significantly lowering costs and radiation exposure.

Forest Devices, Inc. is a medical device company based in Pittsburgh, Pennsylvania, with an additional office in Canada. Founded in 2014, the company focuses on developing innovative solutions for stroke detection. Its primary product, AlphaStroke, is a portable and non-invasive stroke screening device that assists medical personnel in identifying early signs of both ischemic and hemorrhagic strokes. This device is designed to be low-cost and durable, enabling pre-hospital providers to triage patients effectively and make timely decisions regarding their care. By improving the speed and accuracy of stroke detection, Forest Devices aims to reduce delays in critical treatment for patients experiencing strokes.

ClearCam provides clinicians with innovative tools and technologies that improve their vision and skill in the operating room. ClearCam was founded in 2018 and is headquartered in Austin, Texas.

HEPTA Medical is a medical technology company focused on developing a microwave ablation platform for the treatment of early lung cancer. The company's innovative solution includes a microwave ablation catheter equipped with a proprietary temperature sensor, which allows healthcare professionals to monitor and control the ablation volume in real-time. This technology aims to provide a minimally invasive, nonsurgical treatment option, enhancing the efficiency and safety of cancer ablation procedures. By enabling precise control over the size of the lesion being treated, HEPTA Medical seeks to improve patient outcomes in cancer care.

Olfactomics is a Finnish university-based spinoff company focused on advancing surgical tissue assessment technology, particularly in breast-conserving lumpectomies. The company has developed innovative energy-based surgical instruments that analyze surgical smoke, which contains critical information about the operated tissue. This real-time analysis enhances the surgeon's situational awareness during procedures, allowing for the detection of cancerous tissue at margins that might otherwise be overlooked. By improving the accuracy of tumor removal in a single operation, Olfactomics aims to minimize the resection of healthy tissues and reduce the likelihood of costly re-operations.

ThermopeutiX specializes in medical technology, focusing on innovative and cost-effective therapeutic solutions for vascular-related disorders and other medical conditions. The company develops products that address various diseases, particularly through its catheter technology, which aids in the treatment of cerebral hypothermia. These advancements support medical professionals in fields such as neuroradiology, neurosurgery, neurology, and oncology, ultimately enhancing patient care and treatment outcomes.